




How it all Began April 2009 Clinical Trial Update

By Jerry Call

LRG Science Coordinator


By Jim Hughes

LRG Clinical Trials Coordinator

Unlike many types of cancer, clinical trials have been an important part of the lives of many GIST patients. This close association began in the summer of 2000. At that time most GIST patients did not even know they had GIST. GIST was considered a subtype of leiomyosarcoma (LMS). At that time leiomyosarcoma (and GIST) was treated with a toxic mix of chemotherapy called MAID. Unfortunately MAID and other types of chemotherapy had little or no effect on GIST.

Word began to arrive in what was at that time the leiomyosarcoma listserv ran by ACOR that a new oral drug was working in a phase II trial for GIST. Life Raft Group Executive Director Norman Scherzer was the first to report dramatic results for his wife, Anita. This was quickly fol-

See GIST History on page 2



Dr. George Demetri of Dana-Farber Cancer Institute has been one of the leaders in clinical trials for GIST

United States

Bevacizumab plus Imatinib Phase

3: This trial continues at over 200 regional cancer centers across the United States. Recently added were major GIST trial sites including Fox Chase Cancer Center, Oregon Health & Science University and the University of Chicago. This first line trial is for patients recently diagnosed with unresectable GIST. The trial exclusion criteria include "No prior imatinib mesylate, Bevacizumab, or other agents targeting KIT, vascular endothelial growth factor (VEGF), VEGF receptor, or platelet-derived growth factor receptor (PDGFR) for advanced disease. These agents may have been used in the adjuvant setting provided no recurrence for ≥ 12 months after completion of therapy." Bevacizumab is an anti-VEGF agent intended to reduce the ability of the

tumor to grow new blood vessels. The trial is intended to answer the question of whether the addition of Bevacizumab to Imatinib will lead to longer progression-free survival. Half the patients will receive Bevacizumab, which is administered intravenously once every three weeks. All patients will receive Imatinib.



US and International

Sunitinib or Imatinib Phase 3:

New sites have opened in Michigan, Nevada, Ohio, Wisconsin, Germany, the United Kingdom and the Republic of Korea. This trial is for patients having progression while on Imatinib at 400 mg. Patients are randomly assigned to receive either 800 mg Imatinib or 37.5 mg Sunitinib daily.

International

IPI-504 Phase 3: This trial is for patients failing both Imatinib and Sunitinib. It now has multiple new sites in Australia, Belgium, France, Germany, Sweden and the Republic of Korea. IPI-504 is a HSP-90 inhibitor administered intravenously. Patients are randomized to receive either IPI-504 or a placebo.

Nilotinib Versus Imatinib Phase

See Trials Update on page 2

Trials Update from page 1

3: This trial for first line patients is now recruiting at two sites in Canada, and one each in Austria and Spain. In the US 19 sites, 11 states are listed in clinicaltrials.gov along with detailed contact information. All are listed as 'Not yet recruiting'. That could change quickly.

This phase 3 trial will test whether nilotinib (also known as AMN107 and Tasigna) given as initial treatment for metastatic GIST is better than the current initial therapy, imatinib (Gleevec). Nilotinib is a more powerful inhibitor of KIT and PDGFRA than Gleevec. Lab tests also show it is more effective than imatinib against both wild-type GIST and the exon 13 mutant GIST. Nilotinib also showed higher concentrations levels inside GIST tumor cells in the lab.

Patients entering the trial will be randomized to receive either imatinib or nilotinib. Estimated enrollment for the trial will be 736 patients.

GIST History from page 1

lowed by similar reports from Gary Golnik. Gary's wife, Mary, was being treated at Dana-Farber Cancer Institute and Gary and Mary met a few other GIST patients in the trial and arranged to keep in touch about side effects and the trial. This group of patients was the very beginning of what we now know as the Life Raft Group.

Word quickly spread on the LMS list that patients with abdominal LMS might instead have GIST and they needed to have their tumors tested for a protein called c-Kit (now usually just called KIT). With no other effective options for GIST, the phase II trial quickly enrolled its allotted number of patients. Interest in the trial was so high that the trial quickly expanded to allow 147 patients and it filled within a few months even though it was only recruiting in 4 sites.

Because of the demand from patients that were finding out about Gleevec thanks to ACOR and the early members of the Life Raft Group, and because of

Inclusion Criteria include:

1. Histologically confirmed diagnosis of GIST which is unresectable and/or metastatic and either:


- No prior therapy with imatinib or any investigational therapies (e.g. sunitinib). Note: newly diagnosed patients may have received up to 14 days imatinib treatment for disease management while awaiting study start.
- Recurrent GIST after stopping adjuvant treatment with imatinib and no subsequent treatment with any other investigational therapies (for example sunitinib).

2. At least one measurable site of disease on CT/MRI scan

3. Performance status ≤ 2 (capable of self-care but unable to carry out any work)

4. Normal organ, electrolyte and marrow function

Exclusion Criteria include:



the hard work of the trial investigators in the US, Europe, Asia and Australia, phase III trials were quickly formed and up and running by late 2000/early 2001.

Phase III trial accrual was nearly as quick as the phase II accrual. Word was spreading quickly in the tight sarcoma community of doctors and in the online community of GIST patients. During those early years before Gleevec was approved, almost 2000 GIST patients entered clinical trials. This appreciation of trials and willingness to participate continues today as GIST patients continue to join trials in high numbers.

1. Prior treatment with nilotinib or any other drug in this class or other targeted therapy agents with the exception of adjuvant imatinib.

2. Disease progression during adjuvant therapy with imatinib

3. Prior or concomitant malignancy that is currently clinically significant or currently requires active intervention.

4. Impaired cardiac function

Other protocol-defined inclusion/exclusion criteria may apply

The Life Raft Group

Who are we, what do we do?

The Life Raft Group (LRG) directs research to find a cure for a rare cancer and help those affected through support and advocacy until we do. The LRG provides support, information and assistance to patients and families with a rare cancer called Gastrointestinal Stromal Tumor (GIST). The LRG achieves this by providing an online community for patients and caregivers, supporting local in-person meetings, patient education through monthly newsletters and webcasts, one-on-one patient consultations, and most importantly, managing a major research project to find the cure for GIST.

How to help

Donations to The Life Raft Group, a 501(c)(3) nonprofit organization, are tax deductible in the United States. You can donate by credit card at www.liferaftgroup.org/donate.htm or by sending a check to:
The Life Raft Group
40 Galesi Dr., Suite 19
Wayne, NJ 07470

Disclaimer

We are patients and caregivers, not doctors. Information shared is not a substitute for discussion with your doctor.

US Clinical Trials Listing

Imatinib + Bevacizumab

*Imatinib Mesylate With or Without
Bevacizumab in Treating Patients
With Metastatic or Unresectable
Gastrointestinal Stromal Tumor*

Phase: 3
Conditions: Gastrointestinal Stromal Tumor
Strategy: Block KIT
Block tumor blood vessel growth
NCT #: [NCT00324987](#)
Contact: See each trial site.
Geisinger Clinical & Medical Center - CCOP
Danville, PA
570-271-6413
Albert M. Bernath, MD
Montana Cancer Consortium - CCOP
Billings, MT
406-238-6290
Benjamin Marchello, MD
Dayton Clinical Oncology Program - CCOP
Kettering, OH
937-395-8678
Howard M Gross, MD
Toledo Community Hospital Oncology - CCOP
Toledo, OH
419-255-5433
Paul L. Schaefer, MD
Columbus - CCOP
Columbus, OH
614-443-2267
Philip J. Kuebler, MD
Gibbs Regional Cancer Center - CCOP
Spartanburg, SC
864-560-7050
James Bearden, III, MD
Southeast Cancer Control Consortium - CCOP
Winston-Salem, NC
910-777-3036
James M. Atkins, MD

Syracuse Hematology-Oncology Associate of Central New York - CCOP
East Syracuse, NY
315-472-7504
Jeffrey J. Kirshner, MD

Ozarks Regional - CCOP
Springfield, MO
417-269-4520
John W. Goodwin, MD

Columbia River Oncology Program - CCOP
Portland, OR
503-216-6260
Keith Larimer, MD

Carle Cancer Center - CCOP
Urbana, IL
217-383-3394
Kendrieth Rowland, MD

Metro Minnesota - CCOP
St. Louis Park, MN
592-993-1517
Patrick J. Flynn, MD

Kalamazoo - CCOP
Kalamazoo, MI
269-373-7458
Raymond S. Lord, MD

Iowa Oncology Research Association - CCOP
Des Moines, IA
515-244-7586
Roscoe F. Morton, MD

Wichita - CCOP
Wichita, KS
316-262-4467
Shaker R. Dakhil, MD

Oregon Health Sciences University (OHSU)
Portland, OR
503 494-6594
Michael Heinrich

University of Chicago
Chicago, IL
Clinical Trials Office, 773
-834-7424
Hedy Kindler, MD

Fox Chase Cancer Center
Philadelphia, PA
1-888-FOX-CHASE
Margaret von Mehren, M.D.

Marshfield Medical Research & Education Foundation
Marshfield, WI
715-387-5426
Mohammad Q. Khan, MD, FACP

IPI-504

*Study of IPI-504 in GIST patients
following failure of at least imatinib
and sunitinib*

Phase: 3
Conditions: Gastrointestinal Stromal Tumor
Strategy: Destroy KIT
NCT #: [NCT00688766](#)
Contact: GIST Phase 3 Team
<http://www.ringtrial.com/>
877-504-4634
RINGtrialinfo@infi.com
Dana Farber Cancer Institute
Boston, MA
Tarsha Colon, RN
617 632-5117
tc Colon@partners.org
George Demetri, MD, PhD
Oncology Specialists, Park Ridge
Park Ridge, IL
Laura Magid
847-410-0667
lmagid@oncmcd.net
Pamela Kaiser, MD
New Bern Cancer Center
New Bern, NC
Jenifer Haggard
252-638-0422
jenifer.haggard@quintiles.com
Rick Gorman Jr.M.D.
Fox Chase Cancer Center
Philadelphia, PA
New Patient Office
1-888-FOX-CHASE
Margaret von Mehren, M.D.
City of Hope
Duarte, CA
1-866-434-4673
Warren Chow, MD

Cedars-Sinai Outpatient Cancer Center
Los Angeles, CA
Ginny Naessig
310-423-0721
virginia.naessig@cshs.org
Charles Forscher

UCLA's Jonsson Comprehensive Cancer Center
Los Angeles, CA
310-206-3669
bchmielowski@mednet.ucla.edu
Jackie Hernandez
310-794-6913
Bartosz Chmielowski

Fairview Health Services (University of Minnesota)
Minneapolis, MN
Melisa Spence
612-625-0673
Keith Skubitz, MD

Kootenai Cancer Center
Coeur d'Alene, ID
208 666 2295
Robin Gustin Study coordinator
rgustin@kmc.org
Brian Samuels, MD

Indiana University Simon Cancer Center
Indianapolis, IN
Flynn, Janet
317-274-0972
Elena Chiorean

Massachusetts General Hospital
Charlestown, MA
Barbara Rattner, RN
617-724-2333
brattner@partners.org
Edwin Choy, MD

University of Colorado
Aurora, CO
Tiffany Colvin
720-848-0664
tiffanycolvin@ucdenver.edu
Anthony Elias, MD

Washington Cancer Institute
Washington, DC
Christina Sheeran
202-877-9386
christina.m.sheeran@medstar.net
Denis Preibat, MD

University of Chicago
Chicago, IL
Pamela Lofton
773-702-2036
plofton@medicine.bsd.uchicago.edu
Hedy Kindler, MD

St. Vincent's Comprehensive Cancer Center
New York, NY
212-604-6020
Gerald Rosen, MD
Oregon Health Sciences University (OHSU)
Portland, OR
OHSU Knight Cancer Institute Clinical Trials Hotline
503-494-1080
Michael Heinrich, MD

Masitinib, (AB1010)

Efficacy and Safety of Masitinib (AB1010) in Comparison to Imatinib in Patients With Gastro-Intestinal Stromal Tumour

Phase: 3
Conditions: Gastrointestinal Stromal Tumor
Strategy: Block KIT
NCT #: [NCT00812240](#)
Contact: Antoine Adenis, M.D.
+33 (0)3 20 29 59 59
a-adenis@o-lambret.fr
MD Anderson - Orlando
Orlando, FL
Clinical Trials Office - M.D.
Anderson Cancer Center,
713-792-3245
Jon Trent, MD, PhD
Henry Ford Health System
Detroit, MI

Beth Israel Medical Center
New York, NY

Sunitinib or Imatinib

Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors (Resistant at 400 mg

Phase: 3
Conditions: Gastrointestinal Stromal Tumor
Strategy: Block KIT
NCT #: [NCT00372567](#)
Contact: Pfizer Oncology Clinical Trial Information Service
1-877-369-9753
PfizerCancerTrials@emergin-gmed.com
1-800-718-1021
1-877-369-9753
PfizerCancerTrials@emergin-gmed.com

Evanston Hospital
Evanston, IL
Bruce Brockstein, MD

Glenbrook Hospital
Glenview, IL
Bruce Brockstein, MD

Highland Park Hospital
Highland Park, IL
Bruce Brockstein, MD

Karmanos Cancer Institute
Detroit, MI
all (800) KARMANOS (1-800-527-6266) or e-mail
info@karmanos.org
Anthony Shields, MD

Siteman Cancer Center, Creve Coeur
Creve Coeur, MO

Washington University
St. Louis, MO

Siteman Cancer Center, St. Peters
St. Peters, MO

New York Presbyterian Hospital - Columbia University Medical Center
New York, NY
Robert Taub, MD

Fox Chase Cancer Center
Philadelphia, PA
1-888-FOX-CHASE
Margaret von Mehren, M.D.

Site name unknown,
Farmington Hills 48334
Farmington Hills, MI

Site name unknown,
Henderson 89074
Henderson, NV

Site name unknown, Las
Vegas 89102
Las Vegas, NV

Site name unknown, Las
Vegas 89106
Las Vegas, NV

Site name unknown, Las
Vegas 89148
Las Vegas, NV

Site name unknown,
Cleveland 44195
Cleveland, OH

BIIB021 (CNF2024)

*An Open-Label, 18FDG-PET
Pharmacodynamic Assessment of the
Effect of BIIB021 in Subjects With
Gastrointestinal Stromal Tumors*

Phase: 2
Conditions: Gastrointestinal Stromal
Tumor
Strategy: Destroy KIT
NCT #: [NCT00618319](#)
Contact: Biogen Idec

oncologyclinicaltrials@biogenidec.com

Memorial Sloan-Kettering
Cancer Center
New York, NY
Robert Maki, MD

Site name unknown,
Rochester
Rochester, MN

Nilotinib

Nilotinib in Advanced GIST

Phase: 2
Conditions: Gastrointestinal Stromal
Tumor
Strategy: Block KIT
NCT #: [NCT00782834](#)
Contact: FOX CHASE
1-888-FOX-CHASE (369)
Fox Chase Cancer Center
Philadelphia, PA
1-888-FOX-CHASE
Margaret von Mehren, M.D.

Sorafenib (Nexavar, BAY 43-9006)

*Sorafenib in Treating Patients With
Malignant Gastrointestinal Stromal
Tumor That Progressed During or
After Previous Treatment With*

Phase: 2
Conditions: Gastrointestinal Stromal
Tumor
Strategy: Block KIT + Block KIT
Signal Path
NCT #: [NCT00265798](#)
Contact: Clinical Trials Office -
University of Chicago Cancer
Research
773-834-7424
University of Chicago
Chicago, IL
Clinical Trials Office, 773
-834-7424
Hedy Kindler, MD
**Memorial Sloan-Kettering
Cancer Center**
New York, NY
David D'Adamo, MD, PhD,
212-639-7573
David D'Adamo, MD, PhD
City of Hope
Duarte, CA
Warren A. Chow, MD, (866)
434-4673 xt 64215
Warren A. Chow, MD
Illinois CancerCare
Peoria, IL
John Kugler, MD, (309) 243
-3605
John Kugler, MD

Cancer Care Specialists
Decatur, IL
James Wade III, MD, 217
-876-6617,
jlwade3@sbcglobal.net
James Wade III, MD

USC-Norris Cancer Center
Los Angeles, CA
323-865-3955
lenz@hsc.usc.edu
Hein-Josef Lenz, M.D

UC-Davis
Sacramento, CA
916-734-3771
David Gandara, MD

Central Illinois Hem/Onc
Springfield, IL
217-525-2500
Edem Agamah, MD

University of Michigan
Ann Arbor, MI
734 647-8925
Scott Schuetze, MD

**Medical College of
Wisconsin**
Milwaukee, WI
414 805-4603
Stuart Wong, MD

Imatinib + Sunitinib

*Imatinib Mesylate and Sunitinib in
Treating Patients With
Gastrointestinal Stromal Tumors*

Phase: 1
Conditions: Gastrointestinal Stromal
Tumor
Strategy: Block KIT
NCT #: [NCT00573404](#)
Contact: Cancer Information Program
800-811-8480
**Vanderbilt-Ingram Cancer
Center-Cool Springs**
Franklin, TN
615 343-4128
Jordan Berlin
**Vanderbilt-Ingram Cancer
Center at Franklin**
Franklin, TN
615 343-4128
Jordan Berlin
**Vanderbilt-Ingram Cancer
Center**
Nashville, TN
800 811-8480
Clinical Trials Office

Dasatinib (BMS-354825)

Trial of Dasatinib in Advanced Sarcomas

Phase: 2
Conditions: Gastrointestinal Stromal
Tumor
Strategy: Block KIT + Block KIT
Signal Path
NCT #: [NCT00464620](#)
Contact: Kathleen Granlund
734-930-7607
kegranlund@sarctrials.org
734-930-7607
kegranlund@sarctrials.org

**Arkansas Children's
Hospital**
Little Rock, AR
Bryce Warren
WarrenBryceA@uams.edu
Kimo Stine

Stanford Cancer Center
Palo Alto, CA
Marti Lohman
650-725-6413
mllohman@stanford.edu

Kristen Ganjoo, MD

City of Hope
Duarte, CA
Neeti Arora
626-256-4673 ext. 63019
NArora@coh.org
Warren Chow, MD

**Cedars-Sinai Outpatient
Cancer Center**
Los Angeles, CA
Chi Vu
310-423-2133
CVu@csocc.com
Charles Forscher, MD

**Washington Cancer
Institute**
Washington, DC
Christina Sheeran,
202 877-5371
christina.m.sheeran@medstar.net
Dennis A. Priebat, MD

**Emory Winship Cancer
Institute**
Atlanta, GA
Ernest Evans
404-686-1855
ernest.
evans@emoryhealthcare.org
Gina D'Amato, MD

Kootenai Cancer Center
Coeur d'Alene, ID
Sheryl Gordon
208-666-2093
sgolden@kmc.org
Brian Samuels, MD

**Oncology Specialists, Park
Ridge**
Park Ridge, IL
Kathy Tolzien
847-268-8569
ktolzien@oncmed.net
Pamela kaiser

**Indiana University Simon
Cancer Center**
Indianapolis, IN
Kristen Potter, MS
317-278-6616
krpotter@iupui.edu
Daniel Rushing, MD

**Johns Hopkins Sidney
Kimmel Comp Cancer
Center**
Baltimore, MD
Adult Oncology, 410-955
-8804
Pediatric Oncology, 410-955
-8751
David Loeb, MD, PhD

**Massachusetts General
Hospital**
Charlestown, MA
Anthony Thomas
617-643-5411
athomas2@partners.org
Edwin Choy, MD

**Dana Farber Cancer
Institute**
Boston, MA
Sarah Solomon
617-582-7503
ssolomon1@partners.org
James Butrynski, MD

University of Michigan
Ann Arbor, MI
Gino Metko
734-647-2095
ginom@med.umich.edu
Scott Schuetze, MD, PhD

**Nebraska Methodist
Hospital**
Omaha, NB
Gladys Pierce
402-354-5129
gladys.peirce@nmhs.org
Kirsten Leu, MD

**Pennsylvania Oncology
Hematology Associates**
Philadelphia, PA
Deb Riordan, RN, BS
215-829-6712
[debbieriordan@penncolog
y.com](mailto:debbieriordan@penncolog
y.com)
Arthur Staddon, MD

Fox Chase Cancer Center
Philadelphia, PA
1-888-FOX-CHASE
Margeret von Mehren, M.D.

**University of Pittsburgh
Cancer Center**
Pittsburgh, PA
Lynne Frydrych
412-623-4036
frydrychl2@upmc.edu
Hussein Tawbi, MD, MSc

**MD Anderson Cancer
Center**
Houston, TX
Joanne Gigstad
715-563-0510
jgigstad@mdanderson.org
Shreyas Patel, MD

Sarcoma Oncology Center
Santa Monica, CA
Viky Chua
(310) 552-9999
vikychua@aol.com
Sant Chawla, MD

**University of Iowa
Hospitals and Clinics**
Iowa City, IA
Melanie Frees, RN
319-356-1228
melanie-frees@uiowa.edu
Mohammed Milhem, MD

Doxorubicin + Flavopiridol

*Doxorubicin and Flavopiridol in
Treating Patients With Metastatic or
Recurrent Sarcoma That Cannot Be
Removed By Surgery*

Phase: 1
Conditions: Gastrointestinal Stromal
Tumor
Sarcoma
Strategy: Freeze the cell division cycle
NCT #: [NCT00098579](#)
Contact: David R. D'Adamo, MD,
PhD
212-639-7573
dadamod@mskcc.org
**Memorial Sloan-Kettering
Cancer Center**
New York, NY
David D'Adamo, MD, PhD,
212-639-7573.
David D'Adamo, MD, PhD,
212-639-7573.

SF1126

*A Phase I Open Label, Safety,
Pharmacokinetic and
Pharmacodynamic Dose Escalation
Study in SF1126, a PI Kinase (PI3K)*

Phase: 1
Conditions: Solid Tumors
Strategy: Block KIT Signal Path
NCT #:
Contact: Joyce Ingold RN MSN OCN
TGen Clinical Research
Services @ SHC
Debi & Jerry Bisgrove
Research Pavilion
10510 N. 92nd Street, 2nd
Floor
480 323-1339
jingold@shc.org
**TGen Clinical Research
Services**
Scottsdale, AZ
TGen Clinical Research
Services
Patient Care Coordinator
10460 N. 92nd Street, Suite
206
Scottsdale, AZ 85258
Office 480-323-1339
Fax 480-323-1250
**Indiana University Simon
Cancer Center**
Indianapolis, IN
(317) 278-6942
gchiorea@iupui.edu
Elena Chiorean
Arizona Cancer Center
Tucson, AZ
(520) 694-CURE(2873)
Daruka Mahadevan, MD,
PhD

AUY922

*Phase I-II Study to Determine the
Maximum Tolerated Dose (MTD) of
AUY922 in Advanced Solid
Malignancies, and Efficacy in HER2*

Phase: 1
Conditions: Solid Tumors
Strategy: Destroy KIT
NCT #: [NCT00526045](#)
Contact: 1 800 340-6843
**Dana Farber Cancer
Institute**
Boston, MA
617 632-5053
stephen_hodi@dfci.harvard.edu
Stephen Hodi, MD, PhD
Washington University
St. Louis, MO
800-600-3606 or
info@ccadmin.wustl.edu
Timothy Pluard, MD
Nevada Cancer Institute
Las Vegas, NV
702 822-5433
nvogelzang@nvcancer.org
Nicholas Vogelzang, MD
**David Geffen School of
Medicine at UCLA**
Los Angeles, CA
CBritten@mednet.ucla.edu
310-825-5268
Carolyn Britten, M.D.
Medical College of Georgia
Augusta, GA
706-721-2505
tsamuel@mcg.edu
Thomas Samuel, M.D.
**Cancer Therapy and
Research Center**
San Antonio, TX
210-562-1797
mmita@idd.org
Monica Mita, M.D.
**MD Anderson Cancer
Center**
Houston, TX
Vassiliki
Papadimitrakopoulou, MD
703-792-6363
vpapadim@mdanderson.org
Jon Trent, MD, PhD

BGT226

A Phase I/II Study of BGT226 in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer

Phase: 1
 Conditions: Solid Tumors
 Strategy: Block KIT Signal Path
 NCT #: [NCT00600275](#)
 Contact: Novartis
 800 340-6843
Nevada Cancer Institute
 Las Vegas, NV
 Dianna Tercan
 (702) 822-5483
 Lin-Chi Chen, M.D., Ph.D.
Dana Farber Cancer Institute
 Boston, MA
 Melissa Hohos
 617 632-2201
mhohos@partners.org
 George Demetri, MD, PhD
Massachusetts General Hospital
 Charlestown, MA
 617-726-6225
nisaac1@partners.org
 Stephen Isakoff, MD
Cancer Therapy and Research Center
 San Antonio, TX
 Clinical Studies Referral Office
 Telephone: 210-450-5798
 Fax: 210-616-5844
 E-mail: onctrial@idd.org
 Or contact Dr. Francis Giles directly at (210) 450-3838.

MP470

MP470 in Treating Patients With Unresectable or Metastatic Solid Tumor or Lymphoma

Phase: 1
 Conditions: Advanced Stage Solid Tumors
 Strategy: Block KIT
 NCT #: [NCT00504205](#)
 Contact: TGen Clinical Research
 Services Cancer Care Coordinator
 480-323-1255
South Texas Accelerated Research Therapeutics (START)
 San Antonio, TX
 Anthony Tolcher, MD, (210) 593-5255
 Note: Contact number is not verified.
 Anthony Tolcher, MD
Virginia Piper Cancer Center
 Scottsdale, AZ
 Raoul Tibes, MD, 480-323-1350
 Raoul Tibes, MD, 480-323-1350
TGen Clinical Research Services
 Scottsdale, AZ
 TGen Clinical Research Services
 Patient Care Coordinator
 10460 N. 92nd Street, Suite 206
 Scottsdale, AZ 85258
 Office 480-323-1339
 Fax 480-323-1250

SNX-5422

SNX-5422 in Treating Patients With Solid Tumor or Lymphoma That Has Not Responded to Treatment

Phase: 1
 Conditions: Solid Tumors
 Strategy: Destroy KIT
 NCT #: [NCT00644072](#)
 Contact: Clinical Trials Office - Warren Grant Magnusen Clinical Center
 888-NCI-1937
Warren Grant Magnuson Clinical Center
 Bethesda, MD
 Clinical Trials Office - Warren Grant Magnusen Clinical Center 888-NCI-1937
 Giuseppe Giaccone, MD, PhD

BAY 73-4506

Phase I study of BAY 73-4506

Phase: 1
 Conditions: Solid Tumors
 Strategy: Block KIT
 NCT #:
 Contact: Tracy Dufresne, RN, BSN, OCN, CCRP
 Physician Referral Coordinator
 210 593-5265
tracy.dufresne@start.stoh.com
South Texas Accelerated Research Therapeutics (START)
 San Antonio, TX
 Tracy Dufresne, RN, BSN, OCN, CCRP
 Physician Referral Coordinator
 Phone: 210-593-5265
 Fax: 210-615-1075
 E-mail: tracy
MD Anderson Cancer Center
 Houston, TX
 Clinical Trials Office - M.D. Anderson Cancer Center,
 713-792-3245
 Jon Trent, MD, PhD

BEZ235

A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer

Phase: 1
 Conditions: Solid Tumors
 Strategy: Block KIT Signal Path
 NCT #: [NCT00620594](#)
 Contact: Novartis
 862-778-8300
Nevada Cancer Institute
 Las Vegas, NV
 Dianna Tercan
 (702) 822-5483
 Wolfram Samlowski, M.D.
Sarah Cannon Research Institute
 Nashville, TN
 615-329-7224
 615-986-4347
 hburris@tnonc.com
 Howard A. Burris, III MD

BIIB021 (CNF2024)

Once or Twice Daily Administration of BIIB021 to Subjects With Advanced Solid Tumors

Phase: 1
 Conditions: Solid Tumors
 Strategy: Destroy KIT
 NCT #: [NCT00618735](#)
 Contact: Biogen Idec

oncologyclinicaltrials@biogenidec.com

South Texas Accelerated Research Therapeutics (START)
 San Antonio, TX

GDC-0941

An Open-Label, Phase I, Dose-Escalation Study of PI3 Kinase Inhibitor (GDC-0941) in Patients with Locally Advanced or Metastatic

Phase: 1
 Conditions: Solid Tumors
 Strategy: Block KIT Signal Path
 NCT #:
 Contact:

Dana Farber Cancer Institute
 Boston, MA
 Melissa Hohos
 617 632-2201
 mhohos@partners.org
 George Demetri, MD, PhD

TGen Clinical Research Services
 Scottsdale, AZ
 TGen Clinical Research Services
 Patient Care Coordinator
 10460 N. 92nd Street, Suite 206
 Scottsdale, AZ 85258
 Office 480-323-1339
 Fax 480-323-1250

IPI-493

A Phase I Dose Escalation Study of IPI-493

Phase: 1
 Conditions: Solid Tumors
 Strategy: Destroy KIT
 NCT #: [NCT00724425](#)
 Contact:

Premier Oncology, Scottsdale
 Scottsdale, AZ
 Patricia Shannon, RN
 480 860-5000
 pshannon@premiereoncology.com
 David Mendelson, M.D.

Premier Oncology, Santa Monica
 Santa Monica, CA
 Marilyn Mulay, NP
 310-633-8400
 mmulay@premiereoncology.com
 Lee Rosen M.D.

San Deigo Pacific Oncology and Hematology Associates

Encinitas, CA
 Karen Brady, RN MSN
 760-752-3340
 kbrady@premiereoncology.com
 Richard Just, M.D.

University of Colorado
 Aurora, CO
 Stacy Grolnic, RN
 720-848-0655
 stacy.grolnic@uchsc.edu
 Colin Weeks, MD, PhD

PX-478

Phase I Trial of PX-478

Phase: 1
 Conditions: Solid Tumors
 Strategy: Block related tumor signal paths
 Block tumor blood vessel
 NCT #: [NCT00522652](#)
 Contact:

TGen Clinical Research Services
 Scottsdale, AZ
 Lynne Hull
 480-323-1071
 lhull@shc.org
 Daniel D. Hoff, MD

MD Anderson Cancer Center
 Houston, TX
 Hala Abdulkadir
 713-792-9944
 habdulka@mdanderson.org
 Roy S. Herbst, PhD

PX-866

Phase I Trial of Oral PX-866

Phase: 1
 Conditions: Solid Tumors
 Strategy: Block KIT Signal Path
 NCT #: [NCT00726583](#)
 Contact:

University of Colorado
 Aurora, CO
 Sharon hecker
 720-848-0667
 sharon.hecker@ucdenver.edu
 Antonio Jimeno, MD

MD Anderson Cancer Center
Houston, TX
Rhonda Clement
713-563-3559
rclement@mdanderson.org
Roy Herbst, MD

R1507

A Multiple Ascending Dose Study of R1507 in Children and Adolescents With Advanced Solid Tumors

Phase: 1
Conditions: Solid Tumors
Strategy: Block related tumor signal paths
NCT #: [NCT00560144](#)
Contact: Please reference Study ID Number: PDO_NO21200
973-235-5000 or 800-526-6367 (FOR US ONLY)
973 235-5000

Memorial Sloan-Kettering Cancer Center
New York, NY
212-639-8267
Dr. Tanya Trippett

MD Anderson Cancer Center
Houston, TX
800-392-1611 Patients
800-392-1611 Referring MD
Cynthia E. Herzog

Site name unknown, Denver 80218
Denver, CO

Site name unknown, Bethesda 20982
Bethesda, MD

SNX-5422

Safety and Pharmacology of SNX-5422 Mesylate in Subjects With Refractory Solid Tumor Malignancies

Phase: 1
Conditions: Solid Tumors
Strategy: Destroy KIT
NCT #: [NCT00506805](#)
Contact: Pfizer Oncology Clinical Trial Information 1-877-369-9753
PfizerCancerTrials@emergin-gmed.com
Pfizer CT.gov Call Center 1-800-718-1021
877-369-9753
[PfizerCancerTrials@emergin-gmed.com](#)

TGen Clinical Research Services
Scottsdale, AZ
Joyce Ingold RN MSN OCN
TGen Clinical Research Services
Patient Care Coordinator
10460 N. 92nd Street, Suite 206
Scottsdale, AZ 85258
Office 480-373-1330

Sarah Cannon Research Institute
Nashville, TN
Jessica Gilbert
615 329-7238
Howard A. Burris, III MD

SNX-5422

Safety Study Of SNX-5422 To Treat Solid Tumor Cancers And Lymphomas

Phase: 1
Conditions: Solid Tumors
Strategy: Destroy KIT
NCT #: [NCT00647764](#)
Contact: Pfizer Oncology Clinical Trial Information Service, 1-877-369-9753,
PfizerCancerTrials@emergin-gmed.com
Pfizer CT.gov Call Center, 1-800-718-1021
1-877-369-9753
[PfizerCancerTrials@emergin-gmed.com](#)

Site name unknown, Bethesda 20982
Bethesda, MD
Contact: Pfizer Oncology Clinical Trial Information Service 1-877-369-9753
PfizerCancerTrials@emergin-gmed.com

Sorafenib + Vorinostat

Phase I Vorinostat + Sorafenib in Patients With Advanced Solid Tumors

Phase: 1
Conditions: Solid Tumors
Strategy: Block KIT + Unblock cell death genes + Destroy KIT
NCT #: [NCT00635791](#)
Contact:

University of Colorado
Aurora, CO
Stacy Grolnic
720-848-0655
stacy.grolnic@uchsc.edu
David Ross Camidge MD

STA-9090

Study of STA-9090, Administered Once-Weekly in Patients With Solid Tumors

Phase: 1
 Conditions: Solid Tumors
 Strategy: Destroy KIT
 NCT #: [NCT00687934](#)
 Contact:
Premier Oncology, Santa Monica
 Santa Monica, CA
 310-633-8400
 Lee Rosen
US Oncology - Dayton Oncology & Hematology
 Kettering, OH
 robert.raju@usoncology.com
 (937)293-1622
 Robert Raju

STA-9090

Study of STA-9090, Administered Twice-Weekly in Patients With Solid Tumors

Phase: 1
 Conditions: Solid Tumors
 Strategy: Destroy KIT
 NCT #: [NCT00688116](#)
 Contact:

Dana Farber Cancer Institute
 Boston, MA
 Melissa Hohos, RN,
 617-632-2201
 Geoffrey Shapiro, MD, PhD
Karmanos Cancer Institute
 Detroit, MI
 Dr. Patricia LoRusso
 313-576-8716

Massachusetts General Hospital
 Charlestown, MA
 Pilar De La Roche Mur
 617-632-5841

Beth Israel Deaconess Medical Center
 Boston, MA
 Pilar De La Roche Mur
 617-632-5841

Sunitinib + CP-751

Phase 1 Study of CP-751,871 in Combination With Sunitinib in Patients With Advanced Solid Tumors

Phase: 1
 Conditions: Solid Tumors
 Strategy: Block KIT + Block related tumor signal paths
 NCT #: [NCT00729833](#)
 Contact: Pfizer CT.gov Call Center
 EmergingMed
 800 718-1021
PfizerCancerTrials@emergingmed.com
Premier Oncology, Santa Monica
 Santa Monica, CA
 310 633-8400
 Lee Rosen
South Texas Accelerated Research Therapeutics (START)
 San Antonio, TX

XL147

Study of the Safety and Pharmacokinetics of XL147 in Adults With Solid Tumors

Phase: 1
 Conditions: Solid Tumors
 Strategy: Block KIT Signal Path
 NCT #: [NCT00486135](#)
 Contact: Exelixis Contact Line
 866-939-4041
Dana Farber Cancer Institute
 Boston, MA
 Pilar de la Rocha Mur
 617-632-5841
pilar_DeLaRochaMur@dfci.harvard.edu
 Geoffrey Shapiro, MD
Mary Crowley Medical Research Center
 Dallas, TX
 J.R. Dolan
 214-658-1943
 Gerald Edelman MD, PhD

XL765

Study of the Safety and Pharmacokinetics of XL765 in Adults With Solid Tumors

Phase: 1
 Conditions: Solid Tumors
 Strategy: Block related tumor signal paths
 NCT #: [NCT00485719](#)
 Contact: Exelixis Contact Line
 866-939-4041
Karmanos Cancer Institute
 Detroit, MI
 Theresa Laeder 313-576-9386
 Patricia LoRusso, DO
South Texas Accelerated Research Therapeutics (START)
 San Antonio, TX
 Gina Mangold, MBA 210-413-3594
gmangold@start.stoh.com
 Kyriakos Papadopoulos, MD

International Clinical Trial Update

Sunitinib

*Safety And Efficacy Study Of
Sunitinib Malate In Chinese Patients
With Imatinib Resistant Or
Intolerant Malignant*

Phase: 4
Conditions: Gastrointestinal Stromal
Tumor
Strategy: Block KIT
NCT #: [NCT00793871](#)
Contact: Pfizer Oncology Clinical
Trial Information Service 1
-877-369-9753
PfizerCancerTrials@emergin
gmed.com
Pfizer CT.gov Call Center 1
-800-718-1021
1-877-369-9753

**Site name unknown Beijing
100035**
Beijing, China

**Site name unknown Beijing
100071**
Beijing, China

**Site name unknown, Nanjing
210002**
Nanjing, Jiangsu, JiangsuChina

**Site name unknown, Beijing
100021**
Beijing, China

IPI-504

*Study of IPI-504 in GIST patients
following failure of at least imatinib
and sunitinib*

Phase: 3
Conditions: Gastrointestinal Stromal
Tumor
Strategy: Destroy KIT
NCT #: [NCT00688766](#)
Contact: GIST Phase 3 Team
<http://www.ringtrial.com/>
877-504-4634
RINGtrialinfo@infi.com
Flinders Medical Center
Bedford Park, SA, SAAustralia
Alison Richards
+08 8204 4830
Chris Karapetis

Ashford Cancer Center
Ashford, SA, SAAustralia
Sara McLaughlin
+08 8351 0211
Dusan Kotasek

GM HOCA Research Center
Auchenflower, Queensland,
QueenslandAustralia
Alice lau
+61 7 3737 4572
Paul Eliadis, MD

**Cliniques Universitaires Saint
Luc**
Brussels, Belgium
+0032 2 764 10 37
Yves Humblet, MD

Asan Medical centre
Seoul, Republic of Korea
MoYoul Beck
+82 2 3010 6110
Prof. Yoon-Koo Kang

Prince of Wales Hospital
Randwick, NSW,
NSWAustralia
Daisy Buchanan
+61 2 9382 2574
Prof. David Goldstein

**Peter McCallum Cancer
Centre**
East Melbourne, VIC,
VICAustralia
Jill Davison
+61 3 9656 1111
Grant McArthur, MD

St Augustinus Ziekenhuis
Wilrijk, Brussels,
BrusselsBelgium
Hide Haes
+32 (0) 3 443 3759
Luc Dirix, MD

Institut Gustave-Roussy
Villejuif Cedex, France
Rosa Da Silva
+33 (0)1 42 11 61 73
Axel Le Cesne

St. Herblain
Nantes, France

Helios Klinikum Bad Saarow
Bad Saarow, Germany
Simone Micheel
+49 (0) 336 317 3728
Peter Reichardt, MD

**Universitätsklinikum Essen,
West Germany Cancer
Center**
Essen, Germany
Edel O' Halloran
+49 (0) 201 723 3147
Sebastian Bauer, MD

**Medizinische Hochschule
Hannover**
Hannover, Germany
Kathleen Schutte
+49 (0) 511 532 9196
Victor Grunwald, MD

**Universitätsklinikum
Mannheim**
Mannheim, Germany
Sonja Kogel
+49 (0) 621 383 2042
Peter Hohnberger, MD

Samsung Medical Center
Seoul, Republic of Korea
JiYun Park
jy0650.park@samsung.com
Prof. Joon Oh Park

Lund University Hospital
Lund, Sweden
Irene Schonstrom
+46 46 177 520
Mikael Eriksson, MD

**Onkologiska Kliniken,
Norrlands
Universitetssjukhus**
Umea, Sweden
Marianne Sjodin
+46 90 785 2908
Martin Erlanson, MD

Centre Rene Gauducheau
Nantes, France

Hopital Jean Minjoz
Besancon, France

Institut Paoli Calmette
Marseilles, France
Patrice Viens, MD, PhD

Centre Val d'Aurele
Montpellier, France

Hopital de la Source
Orleans, France

**Hopital European Georges
Pompidou**
Paris, France

Institut Bergonie
Bordeaux, France
Binh Bui Nguyen, MD

Hopital Robert Debre
Reims, France

Hopital Saint-Georges
Beirut, Lebanon

Hopital Saint-Joseph
Dora, Lebanon

**Middle East Institute of
Health**
Bsalm, Lebanon

Hamoud Hospital
Saïda, Lebanon

American University Hospital
Beirut, Lebanon

**Regional Cancer center
University of Ottawa**
Ottawa, Ontario,
OntarioCanada
613-737-7700 xt 79556

Tim Asmis, MD

**Maisonneuve-Rosemont
Hospital**
Montreal, QC, QCCanada
514-252-3489
Lucas Sideris, MD

University Hospital La Paz
Madrid, Spain
34-1-2071138
cbelda.hulp@salud.madrid.org
Cristobal Belda-Iniesta, MD

Masitinib, (AB1010)

*Efficacy and Safety of Masitinib
(AB1010) in Comparison to Imatinib
in Patients With Gastro-Intestinal
Stromal Tumour*

Phase: 3
Conditions: Gastrointestinal Stromal
Tumor
Strategy: Block KIT
NCT #: [NCT00812240](#)
Contact: Antoine Adenis, M.D.
+33 (0)3 20 29 59 59
a-adenis@o-lambret.fr

Centre Oscar Lambret - Lille
Lille, France
Antoine Adenis, MD

Centre Leon Berard
Lyon, France
+33607507064
blay@lyon.fnclcc.fr
Jean Yves-Blay, MD, PhD

**Centre Georges Francois
Leclerc**
Dijon, France

Hopital Charles Nicolle
Rouen, France

**Centre Hospitalier Victor
Jousselin**
Dreux, France

Centre Rene Huguenin
Saint-Cloud, France

Nilotinib or Imatinib

*Phase III, Open-Label Study of
Nilotinib Versus Imatinib in GIST
Patients*

Phase: 3
Conditions: Gastrointestinal Stromal
Tumor
Strategy: Block KIT
NCT #: [NCT00785785](#)
Contact: Novartis Pharmaceuticals
+1-800-340-6843

**Universitätsklinik f. Innere
Medizin**
Vienna, Austria
Thomas Brodowicz, MD

Sunitinib or Imatinib

*Safety And Effectiveness Of Daily
Dosing With Sunitinib Or Imatinib In
Patients With Gastrointestinal
Stromal Tumors (Resistant at 400 mg*

Phase: 3
Conditions: Gastrointestinal Stromal
Tumor
Strategy: Block KIT
NCT #: [NCT00372567](#)
Contact: Pfizer Oncology Clinical
Trial Information Service
1-877-369-9753
PfizerCancerTrials@emergin-gmed.com
1-800-718-1021
1-877-369-9753
PfizerCancerTrials@emergin-gmed.com

**Site name unknown,
Hamburg 22767**
Hamburg, Germany

**Site name unknown, Lai Chi
Kok 0**
Lai Chi Kok, Kowloon,
KowloonHong Kong SAR

**Site name unknown, Tuen
Mun 0**
Tuen Mun, New Territories,
New TerritoriesHong Kong
SAR

Istituto Nazionale Dei Tumori
Milan, Italy
Paolo Casali MD

Site name unknown, Bologna 40138
Bologna, Italy

Site name unknown, San Giovanni Rotondo 71013
San Giovanni Rotondo, Foggia, FoggiaItaly

Site name unknown, Seoul 135-710
Seoul, Republic of Korea

Site name unknown, Seoul 138-736
Seoul, Republic of Korea

Site name unknown, Barcelona 08036
Barcelona, Spain

Site name unknown, Valencia 46009
Valencia, Spain

Christie Hospital NHS Trust
Manchester, Lancashire, LancashireUK

Royal Marsden Hospital
London, UK

Southwest German Cancer Center at Eberhard-Karls University
Tuebingen, Germany
49-707-1298-2127
joerg.hartmann@med.uni-
Joerg T. Hartmann, MD

Site name unknown, Mannheim
Mannheim, Germany

Site name unknown, Goettingen 37075
Goettingen, Germany

Site name unknown, Glasgow G12 0YH
Glasgow, UK

Site name unknown, London NW1 2PG
London, UK

Site name unknown, Seoul 110-744
Seoul, Republic of Korea

Site name unknown, London W1
London, UK

Dasatinib (BMS-354825)

Dasatinib as First-Line Therapy in Treating Patients With Gastrointestinal Stromal Tumors

Phase: 2
Conditions: Gastrointestinal Stromal Tumor
Strategy: Block KIT + Block KIT Signal Path
NCT #: [NCT00568750](#)
Contact: Centre Hospitalier Universitaire Vaudois
Lausanne, Switzerland, CH -1011
41-21-314-0150
Centre Hospitaleir Universitaire Vaudois
Lausanne, Switzerland
41-21-314-0150
Michael Montemurro, MD

Imatinib

Imatinib Mesylate in Treating Patients With Liver Metastasis From a Gastrointestinal Stromal Tumor

Phase: 2
Conditions: Gastrointestinal Stromal Tumor
Strategy: Block KIT
NCT #: [NCT00764595](#)
Contact: Tatsuo Kanda, MD
Niigata University Medical and Dental Hospital
81-25-227-2228
Niigata University Medical and Dental School
Niigata, Japan
81-25-227-2228
Tatsuo Kanda, MD

Imatinib + RAD001

Treatment of Patients With Everolimus and Imatinib Mesylate Who Have Progressive Gastrointestinal Stromal Tumors (GIST)

Phase: 2
Conditions: Gastrointestinal Stromal Tumor
Strategy: Block KIT
Block KIT Signal Path
NCT #: [NCT00510354](#)
Contact: Novartis Basel
41 61 324 1111

Site name unknown, Bad Saarow
Bad Saarow, Germany

Site name unknown, Koln
Koln, Germany

Site name unknown, Dusseldorf
Dusseldorf, Germany

Site name unknown, Frankfurt
Frankfurt, Germany

Site name unknown, Mannheim
Mannheim, Germany

Site name unknown, Munchen
Munchen, Germany

Site name unknown, Tubingen
Tubingen, Germany

Site name unknown, Essen
Essen, Germany

Site name unknown, Hannover
Hannover, Germany

Nilotinib

Efficacy and Safety of AMN107 in Patients With GastroIntestinal Stromal Tumors (GIST) Who Have Failed Both Imatinib and Sunitinib

Phase: 2
 Conditions: Gastrointestinal Stromal Tumor
 Strategy: Block KIT
 NCT #: [NCT00718562](#)
 Contact: Novartis Japan 81 3 3797 8748 Novartis US 862 -778-8330

Site name unknown, Hokkaido
 Hokkaido, Japan

Site name unknown, Niigata
 Niigata, Japan

Site name unknown, Chiba
 Chiba, Japan

Site name unknown, Tokyo
 Tokyo, Japan

Site name unknown, Kyushu
 Kyushu, Japan

Site name unknown, Aichi
 Aichi, Japan

Site name unknown, Osaka
 Osaka, Japan

Site name unknown, Shizuoka
 Shizuoka, Japan

Nilotinib

Phase II Study Aiming to Evaluate the Efficacy and Safety of Nilotinib Patients With Gastrointestinal Stromal Tumors (GIST) Resistant or

Phase: 2
 Conditions: Gastrointestinal Stromal Tumor
 Strategy: Block KIT
 NCT #: [NCT00633295](#)
 Contact: Novartis Basel 41 61 324 1111

Site name unknown, Tel Aviv
 Tel Aviv, Israel

Site name unknown, Tel Hashomer
 Tel Hashomer, Israel

Nilotinib

Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib. (OPEN)

Phase: 2
 Conditions: Gastrointestinal Stromal Tumor
 Strategy: Block KIT
 NCT #: [NCT00756509](#)
 Contact: + 41 61 324 1111

Site name unknown, Bad Saarow
 Bad Saarow, Germany

Surgery

Surgery in Treating Patients With Liver Metastasis From a Gastrointestinal Stromal Tumor

Phase: 2
 Conditions: Gastrointestinal Stromal Tumor
 Strategy: Surgery
 NCT #: [NCT00769782](#)
 Contact: Tatsuo Kanda, MD
 Niigata University Medical and Dental Hospital
 81-25-227-2228
Niigata University Medical and Dental School
 Niigata, Japan
 81-25-227-2228
 Tatsuo Kanda, MD

Radiation

Radiation Therapy as Palliative Treatment of GIST (GIST-RT)

Phase: 1
 Conditions: Gastrointestinal Stromal Tumor
 Strategy: Radiation
 NCT #: [NCT00515931](#)
 Contact: Heikki Joensuu, M.D., Ph.D.
 947173208 Ext. 358
heikki.joensuu@hus.fi
Helsinki University Central Hospital
 Helsinki, Finland
 Heikki Joensuu, M.D., Ph.D.
 947173208 Ext. 358 heikki.
 Heikki Joensuu, MD

Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors

Phase: 4
Conditions: Gastrointestinal Stromal Tumor
Strategy: Block tumor blood vessel growth
NCT #: [NCT00777504](#)
Contact: C.M.L. van Herpen, Md, PhD
31 24 3610353
vanherpen@onco.umcn.nl
University Medical Center Nijmegen st Raboud
Nijmegen, Gelderland,
Gelderland/Netherlands
Contact: C.M.L. van Herpen, Md, PhD
31 24 3610353
C.M.L. van Herpen, Md, PhD

Everolimus

Treatment of Patients With RAD001 Who Have Progressive Sarcoma

Phase: 2
Conditions: Sarcoma
Strategy: Block KIT Signal Path
NCT #: [NCT00767819](#)
Contact: Novartis Basel +41 61 324 1111
Novartis US 862-778 -8300
Site name unknown, Berlin
Berlin, Germany
Site name unknown, Munchen
Munchen, Germany
Site name unknown, Dusseldorf
Dusseldorf, Germany
Site name unknown, Mannheim
Mannheim, Germany

Imatinib + IL-2

Imatinib + IL-2

Phase: 1
Conditions: Gastrointestinal Stromal Tumor
Strategy: Block KIT + Stimulate the immune system
NCT #:
Contact: Dr Patricia Pautier
téléphone direct/standard : - / 01 42 11 42 11
courriel : -

Institut Gustave Roussy (IGR)
+33 (0)1 42 11 42 10
lannes@igr.fr
Institut Gustave-Roussy
Villejuif Cedex, France
Dr Patricia Pautier
téléphone direct/standard : - / 01
Laurence Zitvogel

Multi-bacteria vaccine (MBV)

A Phase I Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen.

Phase: 1
Conditions: Gastrointestinal Stromal Tumor
Strategy: Stimulate the immune system
NCT #: [NCT00623831](#)
Contact: Krankenhaus Nordwest
Frankfurt, Germany
Antje Neumann
069 7601 4161
neumann.antje@khnw.de
Krankenhaus Nordwest
Frankfurt, Germany
Elke Jaeger, MD

AUY922

Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2

Phase: 1
Conditions: Solid Tumors
Strategy: Destroy KIT
NCT #: [NCT00526045](#)
Contact: 1 800 340-6843
Site Name unknown, Bellinzona
Bellinzona, Switzerland

BGT226

A Phase I/II Study of BGT226 in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer

Phase: 1
Conditions: Solid Tumors
Strategy: Block KIT Signal Path
NCT #: [NCT00600275](#)
Contact: Novartis
800 340-6843
Hospital Vall d'Hebron
Barcelona, Spain
Princess Margaret Hospital
Toronto, ON, ONCanada
Lillian Siu, M.D.

XL147

*Study of the Safety and
Pharmacokinetics of XL147 in Adults
With Solid Tumors*

Phase: 1
Conditions: Solid Tumors
Strategy: Block KIT Signal Path
NCT #: [NCT00486135](#)
Contact: Exelixis Contact Line
866-939-4041
Hospital Vall d'Hebron
Barcelona, Spain
Gemma Sala
+34 93 489 4158
Jose Baselga, MD, PhD

XL765

*Study of the Safety and
Pharmacokinetics of XL765 in Adults
With Solid Tumors*

Phase: 1
Conditions: Solid Tumors
Strategy: Block related tumor signal
paths
NCT #: [NCT00485719](#)
Contact: Exelixis Contact Line
866-939-4041
Hospital Vall d'Hebron
Barcelona, Spain
Gemma Sala +34 93 489
4158 gsala@vhebron.net
Jose Baselga, MD, PhD